References
- Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 2012; 39:323 - 39; http://dx.doi.org/10.1053/j.seminoncol.2012.02.006; PMID: 22595055
- Joudeh J, Claxton D. Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms. Expert Opin Investig Drugs 2012; 21:363 - 73; http://dx.doi.org/10.1517/13543784.2012.652302; PMID: 22324354
- Farsaci B, Sabzevari H, Higgins JP, Di Bari MG, Takai S, Schlom J, Hodge JW. Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer 2010; 127:1603 - 13; http://dx.doi.org/10.1002/ijc.25177; PMID: 20091862
- Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, Gulley JL, Schlom J, Farsaci B. Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol 2014; 192:2622 - 33; http://dx.doi.org/10.4049/jimmunol.1301369; PMID: 24516200
- Wang M, Windgassen D, Papoutsakis ET. A global transcriptional view of apoptosis in human T-cell activation. BMC Med Genomics 2008; 1:53; http://dx.doi.org/10.1186/1755-8794-1-53; PMID: 18947405
- Hudson SG, Halleran DR, Nevaldine B, Shapiro A, Hutchison RE, Hahn PJ. Microarray determination of Bcl-2 family protein inhibition sensitivity in breast cancer cells. Exp Biol Med (Maywood) 2013; 238:248 - 56; http://dx.doi.org/10.1177/1535370212474582; PMID: 23576806
- Kurtulus S, Tripathi P, Moreno-Fernandez ME, Sholl A, Katz JD, Grimes HL, Hildeman DA. Bcl-2 allows effector and memory CD8+ T cells to tolerate higher expression of Bim. J Immunol 2011; 186:5729 - 37; http://dx.doi.org/10.4049/jimmunol.1100102; PMID: 21451108
- Wojciechowski S, Tripathi P, Bourdeau T, Acero L, Grimes HL, Katz JD, Finkelman FD, Hildeman DA. Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. J Exp Med 2007; 204:1665 - 75; PMID: 17591857
- Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 2012; 72:3439 - 44; http://dx.doi.org/10.1158/0008-5472.CAN-11-3912; PMID: 22761338
- Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 2010; 70:4850 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-10-0283; PMID: 20501849